Company Analysis

Regenxbio Inc. (RGNX)

Nasdaq: RGNX · Biological Products, (No Diagnostic Substances) · Rockville, MD · filing with the SEC since 2013
Grade5.6
◀ Past 7.0● Present 5.4▶ Future 4.7
1 est.

Who runs Regenxbio Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Simpson Curran
Chief Executive Officer. First filing Sep 2015, latest Jul 6, 2026, 21 filings in all.
Officers reporting now
6
of 15 people with a filing in the last fifteen months
Directors reporting now
9
23 people on the record since 2015
Officerssales are open-market, Nov 3, 2025 to Nov 3, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Chan MitchellChief Financial OfficerSep 2024Nov 3, 2026none
Christmas Patrick J.Chief Strategy & Legal OfficerAug 2016Nov 3, 2026none
Malzahn CraigChief Technology OfficerMar 2025Nov 3, 2026none
Pakola SteveChief Medical OfficerApr 2019Nov 3, 20265 · $900,000
Simpson CurranChief Executive OfficerSep 2015Jul 6, 2026none
Mills Kenneth T.President and CEOSep 2015Jun 2, 2026none
Directorssales are open-market, Nov 3, 2025 to Nov 3, 2026
NameRoleFirst filingLatest filingSales, 12 months
Ciongoli Gregory AustindirectorAug 2026Aug 27, 2026none
Bennett JeandirectorSep 2021Jun 2, 2026none
Fox Allan M.directorSep 2015Jun 2, 2026none
Glucksmann AlexandradirectorMay 2018Jun 2, 2026none
Karabelas Argeris NdirectorSep 2015Jun 2, 2026none
Migausky George VdirectorSep 2021Jun 2, 2026none
Stump David CdirectorOct 2015Jun 2, 2026none
Tasse DanieldirectorAug 2016Jun 2, 2026none
Zachary JenniferdirectorJun 2022Jun 2, 2026none
Earlier names on the record9, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton RGNX · research, not advice